Candel Therapeutics, Inc. (CADL) Stock Grade

About Candel Therapeutics, Inc.'s fundamentals

Candel Therapeutics is a biotechnology company with a market capitalization of $819.9 million that reported zero revenue growth year-over-year and generated no net income in its latest annual period, resulting in a net loss. The company does not currently pay a dividend and lacks a meaningful price-to-earnings ratio due to its unprofitable status. As a preclinical-stage biotech firm, Candel's financial metrics reflect the capital-intensive nature of drug development prior to commercial revenue generation.